ReviewPharmaceutics2023
Phytochemicals and Cancer Treatment: Cell-Derived and Biomimetic Vesicles as Promising Carriers.
Review in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Alkaloid-based nanodrug delivery systems: An emerging strategy against drug-resistant bacterial wound infections.International journal of pharmaceutics: X · 2026Review
- From Nature to Nanomedicine: Engineered Plant-Derived Nanovesicles for Skin Disease.International journal of nanomedicine · 2026Review
- Insights on Natural Membrane Characterization for the Rational Design of Biomimetic Drug Delivery Systems.Pharmaceutics · 2025Review
- Development ofPharmaceutics · 2025Article
- Functionalized turmeric nanovesicles for precision delivery of doxorubicin in colorectal carcinoma treatment.Frontiers in pharmacology · 2025Article
- Exploring Marine Alkaloids: A Natural Approach to Cancer Treatment.Current pharmaceutical biotechnology · 2025Review
- Engineered celastrol liposomes with glycyrrhizic acid augment synergistic antitumor efficacy in breast cancer.Frontiers in oncology · 2025Article
- Development of a Novel Co-Amorphous Curcumin and L-Arginine (1:2): Structural Characterization, Biological Activity and Pharmacokinetics.Pharmaceutics · 2024Article
- Advances in nano-delivery of phytochemicals for glioblastoma treatment.Discover nano · 2024Review
- Microfluidic Fabrication of Oleosin-Coated Liposomes as Anticancer Drug Carriers with Enhanced Sustained Drug Release.Materials (Basel, Switzerland) · 2024Article
- Review
- Aptamers for the Delivery of Plant-Based Compounds: A Review.Pharmaceutics · 2024Review
- Lipid-Based Nanoparticles in Delivering Bioactive Compounds for Improving Therapeutic Efficacy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Organic and Biogenic Nanocarriers as Bio-Friendly Systems for Bioactive Compounds' Delivery: State-of-the Art and Challenges.Materials (Basel, Switzerland) · 2023Review
- The Effects of a Curcumin Derivative and Osimertinib on Fatty Acyl Metabolism and Mitochondrial Functions in HCC827 Cells and Tumors.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The majority of anticancer agents currently used derive from natural sources: plants, frequently the ones employed in traditional medicines, are an abundant source of mono- and diterpenes, polyphenols, and alkaloids that exert antitumor activity through diverse mechanisms. Unfortunately, many of these molecules are affected by poor pharmacokinetics and limited specificity, shortcomings that may be overcome by incorporating them into nanovehicles. Cell-derived nanovesicles have recently risen to prominence, due to their biocompatibility, low immunogenicity and, above all, targeting properties. However, due to difficult scalability, the industrial production of biologically-derived vesicles and consequent application in clinics is difficult. As an efficient alternative, bioinspired vesicles deriving from the hybridization of cell-derived and artificial membranes have been conceived, revealing high flexibility and appropriate drug delivery ability. In this review, the most recent advances in the application of these vesicles to the targeted delivery of anticancer actives obtained from plants are presented, with specific focus on vehicle manufacture and characterization, and effectiveness evaluation performed through in vitro and in vivo assays. The emerging overall outlook appears promising in terms of efficient drug loading and selective targeting of tumor cells, suggesting further engrossing developments in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.